Results from a clinical trial have revealed nearly one third (29.2 percent) of patients with advanced melanoma saw their tumors disappear completely on scans after receiving lifileucel TIL therapy alongside an immune checkpoint inhibitor, pembrolizumab, as a first-line treatment.